Please login to the form below

Not currently logged in
Email:
Password:

fast track appraisal

This page shows the latest fast track appraisal news and features for those working in and with pharma, biotech and healthcare.

NICE’s fast-track catapults Skyrizi into market

NICE’s fast-track catapults Skyrizi into market

The drug is one of the first treatments to go through NICE’s fast-track appraisal system, which accelerates the review process and also cuts the standard 90 day implementation period ... This is even faster than J&J’s rival IL-23 inhibitor Tremfya,

Latest news

  • AbbVie’s Skyrizi gets rapid ‘yes’ from NICE AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

    New fast-track appraisal a boon for companies. AbbVie and Boehringer Ingelheim’s new psoriasis treatment Skyrizi has gained fast-track recommendation from NICE, coming less than three months after its ... AbbVie welcomed NICE’s decision, and said it

  • A first for Bluebird and Europe as gene therapy Zynteglo approved A first for Bluebird and Europe as gene therapy Zynteglo approved

    This was thanks to the EMA’s PRIME designation, a fast-track appraisal system particularly focused on cutting edge therapies from smaller-to-medium sized pharma and biotech firms.

  • NICE first fast-track appraisal backs Bayer's Eylea NICE first fast-track appraisal backs Bayer's Eylea

    The National Institute for Health and Care Excellence (NICE) has issued its first fast-track guidance, recommending Bayer’s Eylea (aflibercep) in choroidal neovascularisation (CNV). ... NICE’s fast track procedure is designed to give patients faster

  • NICE to create fast track for most cost-effective new drugs NICE to create fast track for most cost-effective new drugs

    Patients could get access to some medicines three months faster under a new 'fast track' appraisal process proposed by the UK's National Institute for Health and Care Excellence (NICE). ... Medicines qualifying for the fast-track process would have final

  • FDA will give BMS-Pfizer's Eliquis a priority review

    News that the FDA will fast-track its appraisal of the drug comes shortly after UK cost-effectiveness watchdog the National Institute for Health and Clinical Excellence (NICE) issued final draft ... This too was after a fast-tracked review process.

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • NICE – but not enough NICE – but not enough

    This falls to 30 days for products included in the Early Access to Medicines Scheme (EAMS) or those designated for Fast Track Appraisal. ... Let’s start with the assumption that NICE recommendations are implemented within the mandatory 90-day period

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics